LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY
One-hundred and four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single French center over a 10-year period. We attempted to define predictive factors for response and survival. The overall...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-04-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/4144 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032232042856448 |
|---|---|
| author | Xavier Thomas Marica Laurino sandrine loron marie-virginie larcher gaëlle fossard mohamed elhamri alexandre deloire marie balsat fiorenza barraco hélène labussière sophie ducastelle myriam renault eric wattel maël heiblig gilles salles |
| author_facet | Xavier Thomas Marica Laurino sandrine loron marie-virginie larcher gaëlle fossard mohamed elhamri alexandre deloire marie balsat fiorenza barraco hélène labussière sophie ducastelle myriam renault eric wattel maël heiblig gilles salles |
| author_sort | Xavier Thomas |
| collection | DOAJ |
| description | One-hundred and four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single French center over a 10-year period. We attempted to define predictive factors for response and survival. The overall response rate was 70% (86% in newly diagnosed and 67% in relapsed/refractory AML). Disease-free survival (DFS) and overall survival at 3 years after GO treatment was 31% and 29%, respectively. Mortality during induction was 7%. Among remitters, allogeneic hematopoietic stem cell transplantation can be performed in 33 cases (45%). DFS at 3 years was 54%. Incidences of transplant-related mortality, grade ≥ 3 acute graft-versus-host (GvH) disease, and extensive chronic GvH disease were 15%, 12%, and 27%, respectively.No sinusoidal obstruction syndromes were reported among allografted patients as among the other patients in the studied cohort. GO-based chemotherapy is a viable option for treatment of newly diagnosed and relapsed/refractory AML patients, and is a feasible schedule as a bridge to allogeneic transplant. |
| format | Article |
| id | doaj-art-9dcbc623019c4a9b945227c7f867c565 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-9dcbc623019c4a9b945227c7f867c5652025-08-20T02:58:43ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062020-04-0112110.4084/mjhid.2020.020LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDYXavier Thomas0Marica Laurinosandrine loronmarie-virginie larchergaëlle fossardmohamed elhamrialexandre deloiremarie balsatfiorenza barracohélène labussièresophie ducastellemyriam renaulteric wattelmaël heibliggilles sallesLyon-Sud HospitalFranceOne-hundred and four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single French center over a 10-year period. We attempted to define predictive factors for response and survival. The overall response rate was 70% (86% in newly diagnosed and 67% in relapsed/refractory AML). Disease-free survival (DFS) and overall survival at 3 years after GO treatment was 31% and 29%, respectively. Mortality during induction was 7%. Among remitters, allogeneic hematopoietic stem cell transplantation can be performed in 33 cases (45%). DFS at 3 years was 54%. Incidences of transplant-related mortality, grade ≥ 3 acute graft-versus-host (GvH) disease, and extensive chronic GvH disease were 15%, 12%, and 27%, respectively.No sinusoidal obstruction syndromes were reported among allografted patients as among the other patients in the studied cohort. GO-based chemotherapy is a viable option for treatment of newly diagnosed and relapsed/refractory AML patients, and is a feasible schedule as a bridge to allogeneic transplant.https://mjhid.org/index.php/mjhid/article/view/4144acute myeloid leukemia; gemtuzumab ozogamicin; prognosis; treatment |
| spellingShingle | Xavier Thomas Marica Laurino sandrine loron marie-virginie larcher gaëlle fossard mohamed elhamri alexandre deloire marie balsat fiorenza barraco hélène labussière sophie ducastelle myriam renault eric wattel maël heiblig gilles salles LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Mediterranean Journal of Hematology and Infectious Diseases acute myeloid leukemia; gemtuzumab ozogamicin; prognosis; treatment |
| title | LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY |
| title_full | LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY |
| title_fullStr | LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY |
| title_full_unstemmed | LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY |
| title_short | LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY |
| title_sort | lyon university hospital experience with gemtuzumab ozogamicin therapy in acute myeloid leukemia a real life study |
| topic | acute myeloid leukemia; gemtuzumab ozogamicin; prognosis; treatment |
| url | https://mjhid.org/index.php/mjhid/article/view/4144 |
| work_keys_str_mv | AT xavierthomas lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT maricalaurino lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT sandrineloron lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT marievirginielarcher lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT gaellefossard lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT mohamedelhamri lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT alexandredeloire lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT mariebalsat lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT fiorenzabarraco lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT helenelabussiere lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT sophieducastelle lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT myriamrenault lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT ericwattel lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT maelheiblig lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy AT gillessalles lyonuniversityhospitalexperiencewithgemtuzumabozogamicintherapyinacutemyeloidleukemiaareallifestudy |